ctDNA as a Blood-based Biomarker for Immunotherapy Response – Technology Networks
|
ctDNA as a Blood-based Biomarker for Immunotherapy Response
Technology Networks Immunotherapy is giving patients with metastasized NSCLC a second chance at finding the right treatment for them. In fact, with new immunomodulatory drugs like the PD-1 inhibitors pembrolizumab and nivolumab, we've seen patients exhibit durable … |
